In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Oral semaglutide—a key ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

A pill version of Novo Nordisk A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot ...

New research suggests that drugs like Ozempic and Wegovy might trigger more than just a slimmer waistline. Many users have ...

Pill versions of the obesity drugs now taken only as injections are on the way. We look at the science behind the pills and if they might be more affordable and accessible than the shots.

The lower prices stem from the Medicare negotiation program created under the Biden administration's Inflation Reduction Act.

Pharmaceutical company Eli Lilly is looking to roll out a daily weight loss pill for patients with obesity and type 2 ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

GLP-1 medications have been a life-changing tool to help people manage their blood sugar and lose weight. But the most popular forms of these medications have a big drawback: You have to inject ...

A major new clinical trial involving more than 1,600 people has found that a GLP-1 pill form of the drug orforglipron works ...